A Bayesian-NLME approach identifies patients at risk of delayed MTX elimination if informative TDM data is provided

Oncology

Trial design and analysis

Pharmacometrics

Methodology

Klose M, Marschner D, Knott M, Wendler J, Müller-Kühnle J, Kovar L, Huisinga W, Nyhoegen C, Michelet R, Mc Laughlin AM, Illerhaus G, Kloft C.